Kurse werden geladen...
Prognose
Kaufen | 3 |
Halten | 3 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -6 / 13 |
News
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which rep.» Mehr auf businesswire.com
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares.» Mehr auf businesswire.com
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −14,47 Mio | 110,49% |
EBITDA | −14,90 Mio | 106,36% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 68,82 Mio€ |
Anzahl Aktien | 6,58 Mio |
52 Wochen-Hoch/Tief | 24,47€ - 3,51€ |
Dividenden | Nein |
Beta | 2,86 |
KGV (PE Ratio) | −3,19 |
KGWV (PEG Ratio) | −0,22 |
KBV (PB Ratio) | 3,63 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Forte Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium in den Vereinigten Staaten. Es entwickelt das Programm FB-102, das verschiedene Autoimmunkrankheiten wie Vitiligo und Alopecia areata behandelt. Der Hauptsitz des Unternehmens befindet sich in Dallas, Texas.
Name | FORTE BIOSCIENCES INC |
CEO | Paul A. Wagner |
Sitz | Dallas, tx USA |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 14 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | FBRX |
Frankfurt | 37TA.F |
München | 37TA.MU |
Assets entdecken
Shareholder von FORTE BIOSCIENCES INC investieren auch in folgende Assets